EP2023990A1 - Adaptateur avec raccord pour pulvérisateur - Google Patents

Adaptateur avec raccord pour pulvérisateur

Info

Publication number
EP2023990A1
EP2023990A1 EP07729782A EP07729782A EP2023990A1 EP 2023990 A1 EP2023990 A1 EP 2023990A1 EP 07729782 A EP07729782 A EP 07729782A EP 07729782 A EP07729782 A EP 07729782A EP 2023990 A1 EP2023990 A1 EP 2023990A1
Authority
EP
European Patent Office
Prior art keywords
atomizer
amino
phenyl
chloro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07729782A
Other languages
German (de)
English (en)
Inventor
Michael Markert
Michael Pieper
Hans Schmitt
Jürgen Schraivogel
Thomas Trautmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim International GmbH
Publication of EP2023990A1 publication Critical patent/EP2023990A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices

Definitions

  • the invention relates to an adapter with a connection for a nebulizer for, in particular a drug exhibiting fluid as aerosol through a nebulizer nozzle, wherein the port is gekopplet via a bore with a patient-side outlet, and connected to a fluidically connected to the bore Entrance for a breathing air hose to be fastened thereto, that the main atomizing direction of the fluid is aligned parallel to the flow direction of a breathing gas, wherein in an opening associated with the inlet opening parallel to the bore in the direction of the atomizer is inserted.
  • Ventilators are used to supply a patient with a breathing gas via at least one gas-carrying hose line.
  • a ventilated patient with an inflammatory lung disease such as asthma or COPD ("chronic obstructive pulmonary disease")
  • COPD chronic obstructive pulmonary disease
  • topical treatment in the lungs is often beneficial to reduce systemic side effects of the drugs.
  • WO 02/089887 A1 discloses a T-shaped adapter for releasably securing a nebulizer in a breathing circuit, the adapter having a housing with an upper one
  • Section having a first passage therein and a lower portion having a second passage adjacent to the first passage.
  • a spring chamber with a spring Between the first passage and an inner wall surface of the upper portion is a spring chamber with a spring, and a valve seat is formed at an upper edge of the upper portion.
  • the reciprocable valve includes a valve actuator slidably received in the second passage and including a top surface for biasing the spring and a valve member secured to the valve actuator.
  • WO 2004/098689 discloses a nebuliser connection device for connecting a nebuliser to a respiratory air hose of a ventilator, which device comprises a respiratory air supply device with a first connection device for connecting a respiratory air line leading to a respiratory air A second connection device 5 is for connection of a respiratory air line A closure device is provided on the distal connection device, through which a flow path for an aerosol generated by the nebulizer can be closed when connecting the nebulizer.
  • the nebulizer connection device is disadvantageous insofar as the aerosol generated by the nebulizer flows into the respiratory gas in a direction perpendicular to the flow direction of the respiratory gas leading hose line is introduced, wherein a significant impaction and thus a separation of the dissolved in the aerosol 5 active substance in the tubing, resulting in a deficiency of the patient with the active substance is given by the entry angle of the aerosol into the tube leading the breathing gas
  • EP 0 521 061 B1 discloses a dosing device for dispensing a measured amount of a liquid as a spray with droplets of a size suitable for inhalation into the lungs by dispensing the measured amount of liquid through a atomizing means having a chamber for receiving the measured Amount of the liquid, an energy store and means for delivering a predetermined amount of energy to the energy storage device
  • means for releasing the predetermined amount of energy from the energy store are provided on the chamber, so as sensitive liquid to a predetermined pressure rise from a low pressure to a higher pressure and initiate a discharge of the liquid from the chamber.
  • a nebulizer is used to nebulize the metered amount of the pressurized fluid.
  • W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HI antihistamines, PAF- Antagonists and PI3 kinase inhibitors.
  • a pharmacologically active agent selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HI antihistamines, PAF- Antagonists and PI3 kinase inhibitors.
  • two- or three-fold combinations of W can be combined and used for application in the device according to the invention. Exemplary combinations of W would be:
  • W represents a betamimetics combined with an anticholinergic, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists,
  • W represents an anticholinergic agent combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists
  • W represents a corticosteroid combined with a PDE4 inhibitor
  • W represents a PDE4 Inhibitors combined with an EGFR inhibitor or LTD4 antagonist
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolertrol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol , Meluadrine, Metaproterenol, Orciprenaline, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrine, Salmefamol, Salmetrol, Soterenol, Sulphone terol, Terbutaline, Tiaramide, Tolubuterol, Zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate,
  • Hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate Preferred anticholinergic compounds here are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt Trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active ingredients.
  • the abovementioned salts may preferably contain chloride, bromide, iodine, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate , Succinate, benzoate or p-toluenesulfonate, with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions.
  • the chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • anticholinergics are selected from the salts of the formula AC-I
  • X is a singly negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-Toluenesulfonate, preferably a singly negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, optionally in the form of their racemates, enantiomers or hydrates Significance are those drug combinations that the enantiomers of the formula AC-l-en
  • R is either methyl or ethyl and where X ⁇ may have the meanings given above.
  • the compound of the formula AC-2 may also be present in the form of the free base AC-2-base.
  • Preferred corticosteroids are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone , RPR-106541, NS-126, ST-26 and
  • any reference to steroids includes reference to their optionally existing salts or derivatives, hydrates or solvates Examples of possible salts and derivatives
  • the steroids may be: alkali metal salts, for example sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • Preferred PDE4 inhibitors here are compounds selected from the group consisting of enprofylline, theophylline, roflumilast, A-riflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofylline, atizoram, D-4418, bay 198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
  • the acid addition salts of the PDE4 inhibitors are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078 , VUF-K-8707, L-733321 and - l - (((R) - (3- (2- (6,7-Difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2- hydroxy-2-propyl) phenyl) thio) methylcyclopropane-acetic acid,
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • alkali metal salts such as, for example, sodium or potassium salts, alkaline earth salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates. nate, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • Preferred EGFR inhibitors are compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate
  • Compounds which are preferably used as dopamine agomsts are those which are selected from the group consisting of bromocriptine, cabergon, alpha-
  • Dihydroei gocryptin Lisu ⁇ d, Pergohd, Pramipexole, Roxindol, Ropinirol, Talipexol, Tergu- ⁇ d and Viozan, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Hl -Antihistaminika here are preferably compounds used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, Cexchlorpheniramin, pheniramine, doxylamine , Chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclocine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • substance formulations or mixtures of substances all inhalable compounds are used, such. also inhalable macromolecules, as disclosed in EP 1 003 478.
  • substances, substance formulations or substance mixtures are used for the treatment of respiratory diseases, which are used in the inhalation area.
  • the compound may be derived from the group of derivatives of ergot alkaloids, the triptans, the CGRP inhibitors, the phosphodiesterase V inhibitors, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or hydrates.
  • the object is achieved in that the opening extends into a region facing the atomizer behind the atomizer nozzle.
  • the inhaler-shaped atomizer is connected to the adapter for a respiratory system in such a way that a flow channel for the respiratory gas is provided, which ensures that the complete dose of the atomized fluid, ie the complete amount of the aerosol generated by the atomizer, from the respiratory gas is promoted to the patient by the breathing gas is passed behind the atomizer nozzle in the corresponding flow channel and thus entrains the spray cloud.
  • the aerosol generated by the atomizer is taken up directly at the place of its generation by the respiratory gas flowing through the adapter and supplied to the ventilated patient with a slight impaction in the tube, since the main atomizing direction of the fluid is parallel to the flow direction of the respiratory gas.
  • the ventilated patient is supplied with aerosolized active substances and a continuous inhaled medication already carried out with the atomizer can be continued after the patient has been connected to the respiratory system or a medication or active ingredient administration of the patient connected to the respiratory system can take place.
  • a respiratory mask or a tracheal tube or the like can be connected to the patient-side outlet.
  • connection for the atomizer is adapted in its geometry in regions to a mouthpiece of the atomizer into which the atomizer nozzle protrudes and which has at least one recess in an area facing away from the inhalation opening in its wall which communicates with the opening for the respiratory gas Flow connection is.
  • the mouthpiece is provided with two opposing recesses through which the breathing gas or air sucked in by the patient flows, for example to inhale respirable particles of the drug.
  • connection for the atomizer is supported on a shoulder of the atomizer
  • the connection can be sealed to the cylindrical shoulder of the atomizer, for example
  • the opening is formed in the region of the mouthpiece as a groove.
  • the groove is relatively easy to manufacture and after insertion of the mouthpiece into the connection, the groove forms a circumferentially closed flow channel with a corresponding wall of the mouthpiece
  • the breakthrough associated with the inlet for the respiratory gas is perpendicular to the bore.
  • the respiratory gas thus passes into the breakthrough, is diverted at its end into the flow channel formed by the groove and the corresponding wall of the mouthpiece, flows through the recesses into the mouthpiece, into which makes a further directional diversion, and carries the aerosol generated by the nebulizer nozzle into the mouthpiece through the bore to supply the patient with both AT gas and the drug
  • At least one valve is provided, which separates the atomizer from the respiratory gas in terms of flow and directs the respiratory gas from the inlet directly to the patient-side outlet. Sonach can then be used to ventilate the patient either via the atomizer or directly
  • the atomizer for the above-described adapter for dispensing a certain amount of the fluid, in particular having a medicament is formed as an aerosol from the pressure accumulator through the atomizer nozzle arranged inside the mouthpiece, wherein a mechanical pressure generator applies the measured fluid to the pressure accumulator, which is to be released abruptly for atomization, and the mouthpiece has at least one opening which, seen in Zerstaubungs ⁇ chtung, formed behind the nozzle
  • the pressure generator comprises a holder for a fluid receiving replaceable Vorratsbehalter, an associated Ant ⁇ ebsfeder with a Losetaste and a A conveyor tube, wherein an axial clamping of the Ant ⁇ ebsfeder shifts the holder with the Vorratsbehalter and the Forderrohr in a direction opposite to the Mundstuck direction and sucks fluid from the Vorratsbehalter in a pressure chamber and an actuation of the release button En tstrong the strained Ant ⁇ ebsfeder causes the conveyor tube in the direction of the Mund
  • FIG. 1 shows a partial view of a longitudinal section through an inventive adapter A
  • FIG. 2 is a sectional view of an atomizer for use with the adapter of FIG. 1
  • the nebulizer 1 is used for nebulizing a fluid 2, in particular a highly effective drug or the like, and is designed as a portable inhaler which operates without propellant gas in the atomization of the fluid 2, preferably a liquid, an aerosol is formed, which is not a represented user can be inhaled
  • the atomizer 1 has a replaceable storage container 3 with the fluid 2, which essentially has a cylindrical or cartridge-like structure and can be inserted from below into the opened atomizer 1.
  • a bag 4 receiving the fluid 2
  • Fluids 2 in a predetermined adjustable amount comprises the atomizer 1, a pressure generator 5 with a holder 6 for the container 3, a Ant ⁇ ebsfeder 7 with a manually releasable to relax the release button 8, a Forderrohr 9 with an inserted check valve 10, a pressure chamber 11 and a Atomizing nozzle 12, which is associated with a mouthpiece 13
  • the support 6 is moved downwards with the storage container 3 and the delivery pipe 9 and fluid from the container 3 sucked via the check valve 10 into the pressure chamber 11 of the pressure generator 5.
  • the fluid 2 is pressurized in the pressure chamber 11 of the conveying tube 9 upwardly displacing the drive spring 7 and output via the atomizer nozzle 12 under atomization.
  • Atomization takes place, for example, in particles in the ⁇ m or nm range, preferably in respirable particles with a size of about 5 ⁇ m, which form a cloud or a jet of an aerosol. A user can inhale the aerosol, wherein supply air or breathing gas via openings 15 in the mouthpiece 13 is sucked.
  • the adapter 19 is provided which has a connection 20 for the atomizer 1, wherein the connection 20 comprises a region 21 which in its Geometry is adapted to the mouthpiece 13 of the atomizer 1. Opposite the connection 20, the adapter 19 has a patient-side outlet 22, which is in flow communication with the connection 20 via a bore.
  • Passage 24 having the inlet 25, wherein the cylindrical cross-section entrance 25 is aligned with the coaxially extending passage 24 at right angles to the bore 23. Trained as a blind hole passage 24 opens into a groove 26 designed as an opening 27 which extends parallel to the bore 23 and extends to the recesses 15 in the mouthpiece 13, which are located below the atomizer 12.
  • the respiratory gas passes from the breathing air hose into the opening 24 and is diverted at its end into the flow channel formed by the groove 26 and a corresponding wall of the mouthpiece 13, at the end of which the breathing gas passes through the recesses
  • the breathing gas is redirected below the atomizing nozzle 12 again in its flow direction and takes the aerosol generated by the atomizer nozzle 12 in the mouthpiece 13 through the bore 23 with to supply the patient with both breathing gas and with the drug, wherein within the mouthpiece 13, the Hauptzerstäubungsraum a drug is aligned parallel to the flow direction of the breathing gas.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Anesthesiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un adaptateur comprenant un raccord (20) pour un pulvérisateur (1) servant à délivrer un fluide (2), en particulier contenant un médicament, sous la forme d'un aérosol à travers une buse de pulvérisation (12), le raccord (20) étant relié par un perçage (23) à une sortie côté patient (22), et une entrée (25) en communication fluide avec le perçage (23) pour une tubulure d'air destinée à y être raccordée de telle façon que la direction principale de pulvérisation du fluide (2) est orientée parallèlement au sens d'écoulement d'un gaz respiratoire. Une ouverture (27) qui s'étend parallèlement au perçage (23) en direction du pulvérisateur (1) est ménagée dans un passage (24) associé à l'entrée (25). L'ouverture (27) s'étend jusqu'à une zone tournée vers le pulvérisateur (1) à l'arrière de la buse de pulvérisation (12).
EP07729782A 2006-06-02 2007-06-01 Adaptateur avec raccord pour pulvérisateur Withdrawn EP2023990A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006025884A DE102006025884A1 (de) 2006-06-02 2006-06-02 Adapter mit einem Anschluss für einen Zerstäuber
PCT/EP2007/055381 WO2007141201A1 (fr) 2006-06-02 2007-06-01 Adaptateur avec raccord pour pulvérisateur

Publications (1)

Publication Number Publication Date
EP2023990A1 true EP2023990A1 (fr) 2009-02-18

Family

ID=38353123

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07729782A Withdrawn EP2023990A1 (fr) 2006-06-02 2007-06-01 Adaptateur avec raccord pour pulvérisateur

Country Status (5)

Country Link
EP (1) EP2023990A1 (fr)
JP (1) JP2009538655A (fr)
CA (1) CA2653183A1 (fr)
DE (1) DE102006025884A1 (fr)
WO (1) WO2007141201A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7963955B2 (en) 1998-02-27 2011-06-21 Boehringer Ingelheim International Gmbh Container for a medicinal liquid
DE102004001451A1 (de) 2004-01-08 2005-08-11 Boehringer Ingelheim International Gmbh Vorrichtung zum Haltern eines fluidischen Bauteiles
EP2077132A1 (fr) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation
EP2135632A1 (fr) * 2008-06-20 2009-12-23 Boehringer Ingelheim International Gmbh Inhalateur
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
EP2432531B1 (fr) * 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adaptateur, dispositif d'inhalation et pulvérisateur
WO2011064163A1 (fr) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nébuliseur
CA2781792C (fr) 2009-11-25 2019-04-02 Boehringer Ingelheim International Gmbh Nebuliseur
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011160932A1 (fr) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nébuliseur
EP2694220B1 (fr) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Appareil médical pourvu d'un récipient
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (fr) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Pulvérisateur comprenant des moyens de détrompage
WO2014140765A1 (fr) 2013-03-15 2014-09-18 Trudell Medical International Circuit de ventilateur, adaptateur utilisé dans le circuit de ventilateur et leurs procédés d'utilisation
EP3030298B1 (fr) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nébuliseur
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
ES2913297T3 (es) 2014-05-07 2022-06-01 Boehringer Ingelheim Int Nebulizador

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225928A1 (de) * 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
DE19520622C2 (de) * 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
US6725858B2 (en) * 2001-05-07 2004-04-27 Hudson Respiratory Care Inc. Valved aerosol tee adapter assembly
AR034489A1 (es) * 2001-06-15 2004-02-25 Otsuka Pharma Co Ltd Un sistema de inhalacion de polvo seco para la administracion transpulmonar.
DK1509266T3 (da) * 2002-05-16 2009-10-19 Boehringer Ingelheim Int System omfattende en dyse og et holdersystem
DE10320143A1 (de) * 2003-05-06 2004-12-16 Pari GmbH Spezialisten für effektive Inhalation Vernebleranschlussvorrichtung für Beatmungsgeräte oder dergleichen
US20050183718A1 (en) * 2004-02-24 2005-08-25 Boehringer Ingelheim International Gmbh Nebulizer
DE102005029498B4 (de) * 2005-06-24 2007-08-30 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007141201A1 *

Also Published As

Publication number Publication date
WO2007141201A1 (fr) 2007-12-13
CA2653183A1 (fr) 2007-12-13
JP2009538655A (ja) 2009-11-12
DE102006025884A1 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
EP2432531B1 (fr) Adaptateur, dispositif d'inhalation et pulvérisateur
WO2007141201A1 (fr) Adaptateur avec raccord pour pulvérisateur
EP2029205A1 (fr) Pulvérisateur
JP5719291B2 (ja) 吸入器
EP2015811B1 (fr) Pulvérisateur et procédé de pulverisation d'un fluide
EP2066380B1 (fr) Inhalateur
EP2066382B1 (fr) Doseur à piston
WO2007118801A1 (fr) Inhalateur
EP2007459A1 (fr) Inhalateur
MX2011013077A (es) Inhalador.
EP2007458A1 (fr) Inhalateur
EP2004263A1 (fr) Dispositif d'émission de médicaments, magasins à médicaments à cet effet, et procédé pour prélever un médicament d'une chambre à médicament
JP5504156B2 (ja) 吸入器
EP2424603B1 (fr) Dispositif d'inhalation
EP2001601B1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
DE102006044755A1 (de) Inhalator
WO2007110402A1 (fr) Emballage pour inhalateur de poudre multidose avec proprietes optimisees de purge
EP2198972A1 (fr) Réservoir et gicleur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120103